Organon & Co.
For the period ended Dec 31, 2025. Filed Feb 24, 2026.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2025 · Filed Feb 24, 2026
Contents
Restructuring
- Restructuring
During the first quarter of 2025, we implemented additional restructuring initiatives to drive an enterprise-wide operating model optimization that resulted in an approximate 6% headcount reduction. The restructuring activities were initiated to streamline and simplify the Company’s operating model to create more efficient processes and a simplified structure. Restructuring costs include separation costs associated with manufacturing-related headcount reductions.
In prior years, Organon implemented restructuring activities related to the optimization of its internal operations by reducing headcount. As a result of these combined activities, the Company’s headcount was reduced by approximately 5% by the end of 2024.
The following is a summary of changes in severance liabilities related to the restructuring activities included within Accrued and other current liabilities:
| December 31, 2025 | December 31, 2024 | |
|---|---|---|
| Beginning balance | $14 | $61 |
| Severance & severance related costs | 95 | 31 |
| Cash payments and other | (101) | (78) |
| Ending balance | $8 | $14 |
The Company anticipates that there could be additional restructuring activities during 2026.
-82-
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.